Pfizer Q1: Headwinds And Tailwinds From COVID-19

The company reaffirmed 2020 sales and earnings financial guidance, highlighting the resiliency of the business amid a global pandemic, but Pfizer did highlight some potential business challenges.

SC2004_Pfizer_286009616_1200.jpg
Pfizer's biopharmaceutical revenues held up in the first quarter • Source: Shutterstock

Pfizer Inc. expects some pharmaceutical brands will be impacted by stay-at-home orders and fewer physician visits in the second quarter as a result of the global COVID-19 pandemic, but reaffirmed 2020 sales and earnings guidance while reporting first quarter financial results on 28 April.

CEO Albert Bourla said during a same-day conference call that the guidance reflects the strength and resiliency of the business...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.